Host factors associated with outcome from primary human immunodeficiency virus-1 infection

Current Opinion in HIV and AIDS

Volumn 3, Issue 1, 2008, Pages 28-35

  Telenti, Amalio ^a,c   Carrington, Mary ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Genome; HLA antigens; KIR receptors; Viral load

Indexed keywords

CHEMOKINE; CYTOKINE; HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; GENETIC VARIABILITY; GENOME ANALYSIS; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; MODULATION; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINE PRODUCTION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 40349096074     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f18ac0     Document Type: Review

References (61)

1. Centlivre M, Sala M, Wain-Hobson S, Berkhout B. In HIV-1 pathogenesis the die is cast during primary infection. AIDS 2007; 21:1-11.
2. Telenti A, Goldstein DB. Genomics meets HIV. Nat Rev Microbiol 2006; 4:9-18.
3. Davenport MP, Zhang L, Shiver JW, et al. Influence of peak viral load on the extent of CD4+ T-cell depletion in simian HIV infection. J Acquir Immune Defic Syndr 2006; 41:259-265.
4. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873-1883.
5. Lifson JD, Nowak MA, Goldstein S, et al. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 1997; 71:9508-9514.
6. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-579.
7. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947. The first genome-wide association analysis in HIV. This study focuses on the genomic determinants of viral set point in seroconverting individuals. The study emphasizes the role of acquired immunity, and provides a ranking of all possible genes and genetic variants.
8. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498-1506.
9. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41:1053-1056.
10. Cohen MS. Thomas Parran Award Lecture: transmission and prevention of transmission of HIV-1. Sex Transm Dis 2006; 33:338-341.
11. Yamamoto H, Kawada M, Takeda A, et al. Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS ONE 2007; 2:e540.
12. Northfield JW, Loo CP, Barbour JD, et al. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol 2007; 81:5759-5765. One of the limitations of studies that aim to correlate T-cell responses with control of viremia is that it is difficult to discern whether the control of viremia is a consequence of the particular T-cell response or vice versa. This study set out to test the hypothesis that the HIV-1-specific CD8+ T-cell phenotype early in infection predicts control of HIV-1 viral replication.
13. Gilbert PB, DeGruttola VG, Hudgens MG, et al. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis 2003; 188:179-193.
14. Gupta SB, Jacobson LP, Margolick JB, et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis 2007; 195:546-550. Vaccines designed to induce cell-mediated immune responses are unlikely to provide sterilizing immunity but may be associated with reduced viral set points after infection. This study modeled the potential impact of a vaccine that reduces viral set point using natural history data from 311 HIV-1 seroconverters.
15. McDevitt HO. Discovering the role of the major histocompatibility complex in the immune response. Annu Rev Immunol 2000; 18:1-17.
16. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-551.
17. Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004; 4:630-640.
18. Martin MP, Carrington M. Immunogenetics of viral infections. Curr Opin Immunol 2005; 17:510-516.
19. Nolan D, Gaudieri S, Mallal S. Host genetics and viral infections: immunology taught by viruses, virology taught by the immune system. Curr Opin Immunol 2006; 18:413-421.
20. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999; 283:1748-1752.
21. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-411.
22. Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9:928-935.
23. Brumme ZL, Brumme CJ, Chui C, et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J Infect Dis 2007; 195:1694-1704.
24. Gao X, Bashirova A, Iversen AK, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2005; 11:1290-1292.
25. Allen TM, Altfeld M, Yu XG, et al. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 2004; 78:7069-7078.
26. Altfeld M, Addo MM, Rosenberg ES, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003; 17:2581-2591.
27. Feeney ME, Tang Y, Roosevelt KA, et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term nonprogressing child. J Virol 2004; 78:8927-8930.
28. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212-217.
29. Kelleher AD, Long C, Holmes EC, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193:375-386.
30. Moore CB, John M, James IR, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296:1439-1443.
31. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354:453-459.
32. Bhattacharya T, Daniels M, Heckerman D, et al. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007; 315:1583-1586. Escape from T cell-mediated immune responses affects the ongoing evolution of HIV. By applying statistical approaches that account for phylogenetic relationships among viral sequences, the authors show that viral lineage effects rather than immune escape often explain apparent HLA-mediated immune-escape mutations defined by previous analysis methods.
33. Borghesi L, Milcarek C. Innate versus adaptive immunity: a paradigm past its prime? Cancer Res 2007; 67:3989-3993.
34. Bieniasz PD. Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 2004; 5:1109-1115.
35. Zheng YH, Peterlin BM. Intracellular immunity to HIV-1: newly defined retroviral battles inside infected cells. Retrovirology 2005; 2:25.
36. Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family identifies cell compartments. EMBO J 2001; 20:2140-2151.
37. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-650.
38. Blattner WA, Oursler KA, Cleghorn F, et al. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J Infect Dis 2004; 189:1793-1801.
39. Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007; 45:445-448. A strong correlation between initial HIV-1 RNA viral load levels and viral load set point suggests that early interactions between HIV-1 and a new host are important before fully developed adaptive immune response.
40. Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333-1339.
41. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
42. Robinson J, Waller MJ, Stoehr P, Marsh SG. IPD - the Immuno Polymorphism Database. Nucleic Acids Res 2005; 33:D523-D526.
43. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-274.
44. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10:661-671.
45. Collins KL, Chen BK, Kalams SA, et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998; 391:397-401.
46. + T cells during acute infection. Both effector cell subsets respond with similar kinetics during chronic HIV-1 infection, however.
47. Kottilil S, Chun TW, Moir S, et al. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis 2003; 187:1038-1045.
48. Ravet S, Scott-Algara D, Bonnet E, et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007; 109:4296-4305. In response to viral exposition, particular genetic or regulated features of the NK-cell-receptor repertoire of exposed uninfected individuals contribute to their NK-cell potential. This finding might allow NK cells to generate a more rapid and effective immune response to HIV-1, thereby contributing to prevention of infection.
49. Scott-Algara D, Truong LX, Versmisse P, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003; 171:5663-5667.
50. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434.
51. Qi Y, Martin MP, Gao X, et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog 2006; 2:e79.
52. Barbour JD, Sriram U, Caillier SJ, et al. Synergy or independence? Deciphering the interaction of HLA class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog 2007; 3:e43.
53. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol 2005; 175:5222-5229.
54. Yawata M, Yawata N, Draghi M, et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203:633-645. Natural selection drove an allele-level group A KIR haplotype and the HLA-C1 ligand to unusually high frequency in Japanese people, who provide a particularly informative population for investigating the mechanisms by which KIR and HLA polymorphism influence NK-cell repertoire and function for the individual and the population.
55. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740. Allotypes of the NK-cell receptor KIR3DL1 vary in both NK-cell expression patterns and inhibitory capacity upon binding to their ligands, HLA-B Bw4 molecules, present on target cells. Using a sample size of more than 1500 individuals with HIV, the authors show that various distinct allelic combinations of the KIR3DL1 and HLA-B loci strongly influence plasma HIV RNA levels.
56. Gaudieri S, DeSantis D, McKinnon E, et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005; 6:683-690.
57. Mulherin SA, O'Brien TR, Ioannidis JP, et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS 2003; 17:377-387.
58. Altshuler D, Brooks LD, Chakravarti A, et al. A haplotype map of the human genome. Nature 2005; 437:1299-1320.
59. Goldstein DB, Cavalleri GL. Genomics: understanding human diversity. Nature 2005; 437:1241-1242.
60. Syvanen AC. Toward genome-wide SNP genotyping. Nat Genet 2005; 37 (Suppl):S5-S10.
61. Ahmadi KR, Weale ME, Xue ZY, et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 2005; 37:84-89.